CLA

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: weight muscle inflammation

Research Overview

Conjugated linoleic acid (CLA) research has been dominated by studies of its two principal isomers—cis-9,trans-11 (c9,t11) and trans-10,cis-12 (t10,c12)—and by evaluations of CLA mixtures used as supplements. The most studied outcome areas include body composition/obesity, inflammation and immune modulation, cardiometabolic risk (e.g., atherosclerosis-related endpoints), cancer-related outcomes (including colorectal cancer in preclinical contexts), and bone health. A substantial portion of the mechanistic and efficacy literature comes from animal and cell models, where effects are often larger and more consistent than in humans. In parallel, there is a growing body of work on microbial production and delivery of CLA (e.g., Lactobacillus and Bifidobacterium), including how strain selection and culture conditions influence yield and isomer profiles, and how CLA-producing microbes might contribute to host effects via microbial metabolism rather than direct host–microbe interaction.

The strongest evidence supports that CLA is biologically active and that its effects are isomer-dependent, with t10,c12 more consistently linked to anti-adiposity/body fat reduction signals and c9,t11 more often associated with anti-inflammatory activity in preclinical models. Human clinical evidence, however, is less definitive for broad health benefits: reported effects on body composition and other endpoints are variable, and reviews emphasize that positive findings in animals do not reliably translate to consistent clinical benefit. Safety and tolerability considerations are comparatively well characterized in the human-focused literature, with recurring concerns around glucose homeostasis/insulin resistance, hepatic steatosis and liver function markers, oxidative stress, and other context-specific effects (e.g., milk-fat depression in ruminants). Regulatory status (e.g., GRAS approval of certain CLA mixtures in the U.S.) reflects acceptability for use in foods at specified conditions, but does not resolve uncertainties about long-term risk–benefit across populations and doses.

Key research gaps include (i) more rigorous, adequately powered human trials with standardized isomer composition, dosing, duration, and clinically meaningful endpoints; (ii) clearer delineation of isomer-specific mechanisms and identification of which populations (if any) derive net benefit versus harm (e.g., individuals with metabolic syndrome or impaired glucose regulation); and (iii) improved understanding of long-term safety, including liver and metabolic outcomes and potential cancer-related effects in humans. Additional needs include integrating microbiome research with clinical outcomes—testing whether CLA-producing probiotics/fermented foods meaningfully raise intestinal or systemic CLA and whether this translates into health effects—and optimizing microbial biosynthesis and downstream processing to control isomer profiles and purity for food applications. Overall, the field supports biological plausibility and robust preclinical activity, but the clinical efficacy signal remains mixed and safety monitoring remains central as consumption increases.

1. What conditions has CLA been studied for?

  • Obesity / body composition: studied for reducing body fat and improving lean body mass (multiple reviews note “reduces body fat” and “improving lean body mass”).

  • Metabolic syndrome and lifestyle diseases: broadly discussed as a “nutritional avenue” for metabolic syndrome and lifestyle diseases.

  • Glucose metabolism / diabetes-related outcomes: studied for “antidiabetic” effects, but also for adverse effects on “glucose homeostasis” and “insulin resistance.”

  • Cardiovascular disease / atherosclerosis: studied for prevention of atherosclerosis and cardiovascular disease risk markers.

  • Cancer (including colorectal cancer): originally identified as an anticancer component; discussed for anticarcinogenic effects broadly and specifically in colorectal cancer (CRC), including interest in CLA-producing gut bacteria and CLA metabolites in CRC pathways (inflammation, proliferation, apoptosis).

  • Inflammation and immune function: studied for anti-inflammatory and immunomodulatory effects; bifidobacteria-derived CLA is discussed as potentially benefiting immune function.

  • Bone health: studied for improving bone mass/osteosynthesis.

  • Liver-related outcomes: studied for effects on liver function and hepatic steatosis (noted as a safety concern/adverse effect in humans).

  • Oxidative stress: evaluated as a safety consideration (“oxidative stresses”).

2. Does it work in treating those conditions? Summarize the evidence.

  • Overall efficacy in humans is not definitive. One review explicitly notes that while preclinical (animal) data support benefits, “human clinical findings have yet to show definitive evidence of a positive effect.” Another abstract states animal research is generally more positive than human studies.

  • Body fat / body composition: Reviews repeatedly state CLA “reduces body fat” and may improve lean body mass, but the studies reviewed here do not quantify effects or specify consistent clinical outcomes; they also emphasize that human evidence is less consistently positive than animal evidence.

  • Cardiovascular / atherosclerosis: CLA is described as preventing atherosclerosis and reducing cardiovascular diseases in reviews, but the studies also highlight broader uncertainty around trans fatty acids and cardiovascular health and note debate regarding ruminant trans fatty acids and CVD. The studies reviewed here do not present clear human trial endpoints demonstrating cardiovascular benefit.

  • Cancer (including CRC): CLA is described as anticarcinogenic in reviews. For CRC specifically, the studies emphasize mechanistic plausibility and emerging evidence that CLA metabolites produced by certain gut microbes may influence inflammation/proliferation/apoptosis pathways, and propose microbiome-based precision nutrition to increase endogenous CLA production. However, these are largely review/proposal-level statements in the provided text rather than definitive clinical treatment evidence.

  • Inflammation/immune outcomes: CLA is described as anti-inflammatory and immunomodulatory; one review suggests isomer-specific effects (e.g., c9,t11 mainly anti-inflammatory). The studies do not provide specific human clinical effect sizes or consistent outcomes.

  • Glucose metabolism/diabetes-related outcomes: CLA is described as “antidiabetic” in some reviews, but adverse effects on glucose homeostasis and insulin resistance are also reported in humans. This mixed signal suggests uncertainty and potential risk in susceptible individuals.

Net summary from the studies reviewed here: CLA has broad preclinical and mechanistic support across multiple conditions, but human evidence is described as less consistent and not definitive, with notable safety concerns that complicate a “works/doesn’t work” conclusion.

3. What health benefits does it have?

  • Body composition: reduced body fat; possible improvement in lean body mass (noted in reviews).

  • Anti-inflammatory and immunomodulatory effects: modulation of immune and inflammatory responses; some evidence/claims of isomer-specific activity (e.g., c9,t11 emphasized as anti-inflammatory in one review).

  • Anticarcinogenic potential: described as anticancer/anticarcinogenic; CRC-focused reviews highlight potential roles of CLA metabolites (especially microbiota-derived) in pathways related to inflammation, proliferation, and apoptosis.

  • Cardiometabolic markers: described as protective against atherosclerosis/cardiovascular disease and as potentially beneficial for metabolic syndrome/lifestyle diseases (though human evidence is not definitive in the studies reviewed here).

  • Bone health: described as improving bone mass/osteosynthesis.

Important nuance from the studies: many benefits are attributed to the two major isomers (c9,t11 and t10,c12) and/or their mixture, and effects may differ by isomer (e.g., some reviews attribute anti-obesity/antidiabetic effects more to t10,c12, while c9,t11 is emphasized for anti-inflammatory activity).

4. Does it have any downsides or side effects?

  • Glucose dysregulation: adverse effects reported on “glucose homeostasis” and “insulin resistance” in humans (noted as safety considerations in multiple reviews).

  • Hepatic effects: “hepatic steatosis” and effects on “liver functions” are highlighted as concerns in humans.

  • Oxidative stress: “oxidative stresses” are listed among safety considerations.

  • Potential cancer-related harm in some contexts: one abstract mentions “induction of colon carcinogenesis in humans” as an adverse effect that has been reported (this contrasts with other studies emphasizing anticarcinogenic effects, underscoring uncertainty and possible context/isomer/dose dependence).

  • Food-production/animal effects (not directly human side effects but noted in the studies): milk fat inhibition in ruminants (“milk fat depression”), reduced chicken productivity/egg quality, altered growth performance in fish.

Safety context from the studies: CLA (often as a 50:50 isomer mix) is described as GRAS for food use in the US since 2008, but multiple reviews still emphasize the need for “close monitoring” as consumption rises and because known and unknown consequences may exist.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report specific pharmacogenomic findings (i.e., no gene variants are identified that predict benefit or harm from CLA supplementation). They do, however, imply several factors that could plausibly create inter-individual variability:

  • Isomer-specific biology: multiple studies state that physiological effects differ between c9,t11 and t10,c12 isomers, suggesting that responses could vary depending on the isomer mixture consumed (this is not genetics per se, but it is a major modifier of effect).

  • Microbiome-dependent metabolism: several studies emphasize CLA production by gut bacteria (e.g., Bifidobacterium, Lactobacillus) and propose microbiome-based precision nutrition to increase endogenous CLA production, especially in CRC contexts. This points to microbiome composition as a key source of response variability, but it is not the same as host genetic variation.

Conclusion based on the studies: there is no direct evidence here that CLA is beneficial or harmful for particular human genetic variants; the strongest “precision” angle discussed is microbiome-based rather than host-genotype-based.

References

  1. Conjugated linoleic acid (CLA) as a functional food: Is it beneficial or not?
    Sara Badawy, Yanan Liu, Mingyue Guo, Zhenli Liu, Changqing Xie, Marawan A Marawan, Irma Ares, Bernardo Lopez-Torres, Marta Martínez, Jorge-Enrique Maximiliano, María-Rosa Martínez-Larrañaga, Xu Wang, Arturo Anadón, María-Aránzazu Martínez (2023) - Food research international (Ottawa, Ont.)
  2. Implication of conjugated linoleic acid (CLA) in human health.
    Allison Dilzer, Yeonhwa Park (2012) - Critical reviews in food science and nutrition
  3. Bifidobacterium inhibits the progression of colorectal tumorigenesis in mice through fatty acid isomerization and gut microbiota modulation.
    Yang Chen, Huiting Fang, Haiqin Chen, Xiaoming Liu, Jianxin Zhao, Catherine Stanton, R Paul Ross, Wei Chen, Bo Yang (2025) - Gut microbes
  4. Advances in research on microbial conjugated linoleic acid bioconversion.
    Chen Wu, Haiqin Chen, Yongchao Mei, Bo Yang, Jianxin Zhao, Catherine Stanton, Wei Chen (2024) - Progress in lipid research
  5. Conjugated Linoleic Acid: Potential Health Benefits as a Functional Food Ingredient.
    Jun Ho Kim, Yoo Kim, Young Jun Kim, Yeonhwa Park (2016) - Annual review of food science and technology
  6. Metabolic activities and probiotic potential of bifidobacteria.
    D A Russell, R P Ross, G F Fitzgerald, C Stanton (2011) - International journal of food microbiology
  7. Conjugated Linolenic Acid (CLnA) vs Conjugated Linoleic Acid (CLA): A Comprehensive Review of Potential Advantages in Molecular Characteristics, Health Benefits, and Production Techniques.
    Meijun Du, Mengyue Gong, Gangcheng Wu, Jun Jin, Xingguo Wang, Qingzhe Jin (2024) - Journal of agricultural and food chemistry
  8. Health benefits of conjugated linoleic acid (CLA).
    Kazunori Koba, Teruyoshi Yanagita (2014) - Obesity research & clinical practice
  9. Modulation of inflammation and immunity by dietary conjugated linoleic acid.
    Monica Viladomiu, Raquel Hontecillas, Josep Bassaganya-Riera (2016) - European journal of pharmacology
  10. Production of conjugated linoleic acid by lactic acid bacteria; important factors and optimum conditions.
    Ahmad Nasrollahzadeh, Samaneh Mollaei Tavani, Edris Arjeh, Seid Mahdi Jafari (2023) - Food chemistry: X
  11. Conjugated linoleic acid metabolite impact in colorectal cancer: a potential microbiome-based precision nutrition approach.
    Adriana González, Asier Fullaondo, Javier Rodríguez, Cristina Tirnauca, Iñaki Odriozola, Adrian Odriozola (2025) - Nutrition reviews
  12. Systematic evaluation on the effectiveness of conjugated linoleic acid in human health.
    Gitane Fuke, José Laerte Nornberg (2017) - Critical reviews in food science and nutrition
  13. The health promoting properties of the conjugated isomers of α-linolenic acid.
    Alan A Hennessy, R Paul Ross, Rosaleen Devery, Catherine Stanton (2011) - Lipids
  14. Trans fatty acids and cardiovascular health: research completed?
    I A Brouwer, A J Wanders, M B Katan (2013) - European journal of clinical nutrition
  15. Bacterial conjugated linoleic acid production and their applications.
    Bo Yang, He Gao, Catherine Stanton, R Paul Ross, Hao Zhang, Yong Q Chen, Haiqin Chen, Wei Chen (2017) - Progress in lipid research
  16. Dietary fat and gut microbiota: mechanisms involved in obesity control.
    Olívia Gonçalves Leão Coelho, Flávia Galvão Cândido, Rita de Cássia Gonçalves Alfenas (2019) - Critical reviews in food science and nutrition
  17. Research progress on conjugated linoleic acid bio-conversion in Bifidobacterium.
    Yongchao Mei, Haiqin Chen, Bo Yang, Jianxin Zhao, Hao Zhang, Wei Chen (2022) - International journal of food microbiology
  18. Conjugated linoleic acid: A potent fatty acid linked to animal and human health.
    Parisa Shokryzadan, Mohamed Ali Rajion, Goh Yong Meng, Liang Juan Boo, Mahdi Ebrahimi, Maryam Royan, Mahbod Sahebi, Parisa Azizi, Rambod Abiri, Mohammad Faseleh Jahromi (2017) - Critical reviews in food science and nutrition
  19. Relationship between the Composition of Lipids in Forages and the Concentration of Conjugated Linoleic Acid in Cow's Milk: A Review.
    Isabel Cristina Acosta Balcazar, Lorenzo Danilo Granados Rivera, Jaime Salinas Chavira, Benigno Estrada Drouaillet, Miguel Ruiz Albarrán, Yuridia Bautista Martínez (2022) - Animals : an open access journal from MDPI
  20. Human health effects of conjugated linoleic acid from milk and supplements.
    Tracy A McCrorie, Edel M Keaveney, Julie M W Wallace, Nino Binns, M Barbara E Livingstone (2011) - Nutrition research reviews


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!